Similar to Zepbound, the dose is typically increased every four weeks
Ozempic is FDA-approved for two indications: To improve blood sugar control in adults with type 2 diabetes To reduce the risk of major cardiovascular events, such as heart attack or stroke, in adults with type 2 diabetes and heart disease Wegovy is also FDA-approved for two indications: To reduce body weight and maintain weight loss in adults and children ages 12 and up with obesity, as well as in adults with overweight and at least one weight-related health condition To reduce the risk of major cardiovascular events, such as heart attack or stroke, in adults with heart disease and either obesity or overweight Rybelsus is FDA-approved to treat type 2 diabetes by improving blood sugar control
Ozempic is FDA-approved for Type 2 diabetes, while Wegovy is prescribed for chronic weight management
[DOI] [PMC free article] [PubMed] [Google Scholar] 38.Bliddal H, Bays H, Czernichow S, Uddn Hemmingsson J, Hjelmesth J, Hoffmann Morville T, et al